Search
Aureobasidium pullulans var. pullutans
go.drugbank.com/drugs/DB10427ApprovedAureobasidium pullulans var. pullutans is a fungus which can provoke allergic reactions. Aureobasidium pullulans var. pullutans extract is used in allergenic testing.
Phoma exigua var. exigua
go.drugbank.com/drugs/DB10440ApprovedPhoma exigua var. exigua is a fungus which can provoke allergic reactions. Phoma exigua var. exigua extract is used in allergenic testing.
Guanabenz
go.drugbank.com/drugs/DB00629ApprovedWithdrawnGuanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalBrexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM).
Golimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationalThus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate
Products: SIMPONI 50MG ILO I E FERImlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigational[A225836] As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft.
Aluminium
go.drugbank.com/drugs/DB01370ApprovedInvestigationalWithdrawnA metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.
Acadesine
go.drugbank.com/drugs/DB04944InvestigationalAcadesine has been granted Orphan Drug Designation for B-CLL in the EU.
Pentostatin
go.drugbank.com/drugs/DB00552ApprovedInvestigationalA potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosupp...
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalThe use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.